Aspire Biopharma Holdings, Inc.
ASBP
$0.29
-$0.0279-8.78%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.92M | -1.21M | -551.40K | -373.30K | -481.70K |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.52M | -- | -- | -- | -- |
| Change in Net Operating Assets | 601.60K | 965.90K | 90.00K | 143.40K | 275.80K |
| Cash from Operations | -1.81M | -247.20K | -461.40K | -229.90K | -205.90K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 38.30K | 38.30K | 38.30K | 38.30K | 19.20K |
| Cash from Investing | 38.30K | 38.30K | -37.60K | -37.60K | -56.70K |
| Total Debt Issued | 3.05M | 0.00 | 223.70K | 0.00 | 0.00 |
| Total Debt Repaid | -221.40K | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 229.10K | 229.10K | 229.10K | 229.10K |
| Repurchase of Common Stock | -257.60K | -257.60K | -- | -- | -- |
| Issuance of Preferred Stock | 257.60K | 257.60K | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 265.80K | -- | -- | -- | -- |
| Cash from Financing | 3.09M | 229.10K | 452.80K | 229.10K | 229.10K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.33M | 20.10K | 29.60K | 37.50K | 42.40K |